Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Portfolio Pulse from
Levi & Korsinsky filed a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study and failed to disclose the declining demand for viral-based editing. On January 9, 2025, Intellia announced halting NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 26, 2025 | 1:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics stock price declined after announcing discontinuation of NTLA-3001 research and 27% workforce reduction, with a class action lawsuit alleging securities fraud.
The lawsuit and research discontinuation directly impact Intellia's stock price, investor confidence, and future research strategy, likely causing negative short-term market sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100